智通财经APP讯，心玮医疗-B(06609)发布公告，集团预期于截至2025年12月31日止年度(报告期间)取得收益介乎约人民币4亿元至人民币4.1亿元，较截至2024年12月31日止年度的收益人民币2.78亿元增加至少43.9%。集团亦预计于报告期间取得除税前利润约人民币8000万元，与截至2024年12月31日止年度的除税前净亏损人民币1200万元比较有大幅增长。
收益增长乃受以下因素驱动：缺血性卒中推出的新产品与技术及缺血性卒中产品的市场份额提升;颅内支架的规模化商业化及其他出血性卒中产品销量的增加;及介入通路产品销售的持续增长；及集团透过销售成本及行政开支的有效成本控制措施，降低了集团的费用比率。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.